Evidence map›Paper›PMID 42473469›Full record

ArticleBlood vessels, thrombosis & hemostasis2026

Venous mechanical thrombectomy for deep vein thrombosis in patients with cancer: a single-center prospective study.

Koustav Pal, Joshua D Kuban, Milan Patel, Ketan Shah, Peiman Habibollahi, Varshana Gurusamy, Santosh Mandal, Alda Tam, Sanjay Gupta, Cristhiam M Rojas-Hernandez and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood vessels, thrombosis & hemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Koustav PalDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Joshua D KubanDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Milan PatelDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Ketan ShahDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Peiman HabibollahiDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Varshana GurusamyDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Santosh MandalDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Alda TamDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Sanjay GuptaDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cristhiam M Rojas-HernandezDepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Michael H KrollDepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Vahid Afshar-KharghanDepartment of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Rahul A ShethDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DIANE BODURKA · 1985 to 2026
$290.8M
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinomaR37CA269622 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Rahul Anil Sheth · 2023 to 2026
$1.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R37 CA269622
6 · The paper itself

Abstract

To evaluate safety, efficacy, and clinical outcomes following venous mechanical thrombectomy (MT) for deep venous thrombosis (DVT) in patients with cancer. This single-arm, single-center prospective study evaluated patients with cancer with symptomatic lower extremity or caval DVT treated with venous MT. The primary outcome was clinical success, which was defined as a reduction in the Villalta score by ≥2 points at 6 months. Secondary outcomes included repeat intervention rates and overall survival (OS). Technical success was defined as restoring venous flow with mild (<10%) or no residual filling defect. Twenty-five patients (median age, 63; interquartile range [IQR], 58-71) were included. All patients received anticoagulation. Contraindications to thrombolytics were present in 64% (16/25), and 15 of 25 had indwelling venous devices. Most patients had proximal clot burden, with inferior vena cava and iliac thrombus in 56% and 84%, respectively. Median Villalta scores improved significantly from 10.5 (IQR, 8-14) at baseline to 4 (IQR, 3-6.3) after procedure (Wilcoxon,

Identifiers

PMID42473469
PMCPMC13380791

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.